DARE Dare Bioscience Inc.

1.27
-0.11  -8%
Previous Close 1.38
Open 1.36
Price To Book 14.11
Market Cap 24,997,932
Shares 19,683,411
Volume 1,203,639
Short Ratio
Av. Daily Volume 1,965,956
Stock charts supplied by TradingView

NewsSee all news

  1. Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update

    SAN DIEGO, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on

  2. Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive

    Daré may be entitled to up to $310 million in commercial milestone payments plus tiered royalties on net sales in the double-digits Daré is a clinical-stage biopharmaceutical company committed to the advancement of

  3. Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study

    SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational

  4. Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

    SAN DIEGO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug

  5. Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems

    SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will give one of the feature presentations at the 15th US-Japan Symposium

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b trial planned for 2020.
Sildenafil Cream, 3.6%
Female Sexual Arousal Disorder (FSAD)
Pivotal trial to commence 4Q 2020.
Ovaprene
Contraception
Phase 3 trial to be initiated in 2020.
DARE-BV1
Bacterial Vaginosis
Phase 1 trial planned for 2019.
DARE-HRT1
Hormone replacement therapy

Latest News

  1. Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update

    SAN DIEGO, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on

  2. Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive

    Daré may be entitled to up to $310 million in commercial milestone payments plus tiered royalties on net sales in the double-digits Daré is a clinical-stage biopharmaceutical company committed to the advancement of

  3. Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study

    SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational

  4. Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

    SAN DIEGO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug

  5. Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems

    SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will give one of the feature presentations at the 15th US-Japan Symposium

  6. Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

    SAN DIEGO, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DAR), a leader in women's health innovation, today announced the closing of the previously announced acquisition by merger of privately-held

  7. Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update

    SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today reported financial results for the quarter ended September 30, 2019 and provided a company

  8. Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate

    Across all women and all cycles evaluated, Ovaprene prevented essentially all sperm from entering the cervical canal, a surrogate marker for contraceptive effectiveness.Currently marketed contraceptives with similar

  9. Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform

    SAN DIEGO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DAR), a leader in women's health innovation, today announced it entered into an agreement to acquire privately-held Microchips Biotech, Inc.

  10. Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast

    SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on

  11. Daré Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360

    SAN DIEGO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will be presenting findings from two nonclinical studies at the upcoming

  12. Daré Bioscience to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that Sabrina Johnson, its President and Chief Executive Officer, will present at

  13. Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo

    SAN DIEGO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced a poster presentation at the American Society for Reproductive Medicine (ASRM)

  14. Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference

    SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that David Friend, Ph.D., its Chief Scientific Officer, will present at the 9th

  15. Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics

    SAN DIEGO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the article entitled "Vaginal tamoxifen for treatment of vulvar and vaginal

  16. Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

    SAN DIEGO, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug

  17. Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ:DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will